MVM has been investing in high growth healthcare businesses since 1997. We have a broad, global, investment remit including medical technology, pharmaceuticals, biotechnology, diagnostics, life science tools, and digital health, supported by our investment teams in Boston and London.
Recent updates regarding MVM team, new investments, and portfolio.
Read moreMVM led the Series B financing of GT Medical Technologies, a company dedicated to improving the lives of patients with brain tumors.
Read moreUK government invests in Valneva's manufacturing facility and secures supply of 60 million doses of Valneva's inactivated COVID-19 vaccine VLA2001, with option for another 130 million doses.
Read moreRecent updates regarding MVM team, new investments, and portfolio.
Read moreMVM co-led the Series B financing of Paragon 28, a leading orthopedic foot and ankle company.
Read moreValneva announced an agreement to provide the UK government with up to 100 million doses of its COVID-19 vaccine.
Read moreMVM completed a growth investment in MDxHealth SA, a molecular diagnostic company that markets two proprietary, differentiated tests that optimize the care of patients with prostate cancer.
Read moreMVM led the growth investment round in SkyCell, a company that has developed temperature-control technology to safely transport vaccines and biotechnology drugs
Read moreValneva and Pfizer announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15
Read moreMVM Partners announces the closing of a $325 million healthcare fund, MVM V.
Read moreHLS Therapeutics announces Health Canada approval for Vascepa® to reduce the risk of cardiovascular events
Read moreBiotheranostics launches Not Another Minute campaign for its Breast Cancer Index® test
Read moreVertos Medical completes enrollment in MOTION study of mild® procedure, a minimally invasive treatment for lumbar spinal stenosis
Read moreHLS Therapeutics announces Health Canada grants medical device license for White Blood Cell Point-of-Care Device to be marketed as CSAN® PRONTO™
Read moreValneva has announced that it has completed patient recruitment of the Phase 2 studies for its Lyme disease vaccine candidate, VLA15
Read moreBaxter International Inc, a leading global medical products company, has entered into a definitive agreement to acquire Cheetah Medical, a leading provider of non-invasive hemodynamic monitoring technologies
Read moreMVM invests in HLS Therapeutics Inc which acquires and commercializes branded pharmaceuticals in central nervous system and cardiovascular therapeutic areas for the North American market
Read moreBiotheranostics, Inc. has announced new pivotal data on the Breast Cancer Index (BCI) that further validates its ability to accurately predict which women with early-stage, hormone receptor positive (HR+) breast cancer will benefit from extended endocrine therapy
Read moreValneva reports further positive results for Its Chikungunya vaccine candidate
Read moreMVM Partners LLP has partially divested its stake in Ambio Holdings, Inc., a global leader in peptide manufacturing and development to The Carlyle Group
Read moreWilson Therapeutics AB announces public offer from Alexion Pharmaceuticals
Read more